The therapeutic implications of immunosuppressive tumor aerobic glycolysis

In 2011, Hanahan and Weinberg added Deregulating Cellular Energetics and Avoiding Immune Destruction to the six previous hallmarks of cancer. Since this seminal paper, there has been a growing consensus that these new hallmarks are not mutually exclusive but rather interdependent. The following review summarizes how founding genetic events for tumorigenesis ultimately increase tumor cell glycolysis, which not only supports the metabolic demands of malignancy but also provides an immunoprotective niche, promoting malignant cell proliferation, maintenance and progression. The mechanisms by which altered metabolism contributes to immune impairment are multifactorial: (1) the metabolic demands of proliferating tumor cells and activated immune cells are similar, thus creating a situation where immune cells may be in competition for key nutrients; (2) the metabolic byproducts of aerobic glycolysis directly inhibit antitumor immunity while promoting a regulatory immune phenotype; and (3) the gene programs associated with the upregulation of glycolysis also result in the generation of immunosuppressive cytokines and metabolites. From this perspective, we shed light on important considerations for the development of new classes of agents targeting cancer metabolism. These types of therapies can impair tumor growth but also pose a significant risk of stifling antitumor immunity.

Automated summary

The new hallmarks of cancer relating to metabolism have shown that tumor cells not only benefit from altered cellular energetics, but also create an immunosuppressive microenvironment that promotes their own growth and progression. Development of therapies targeting cancer metabolism needs to carefully consider the balance between inhibiting tumor growth and preserving antitumor immunity.